Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center

• Published in: International journal of environmental research and public health 2019-07, Vol.16 (14), p.2561
• Main Authors: Tai, Yi-Jou, Hsu, Heng-Cheng, Chiang, Ying-Cheng, Chen, Yu-Li, Chen, Chi-An, Cheng, Wen-Fang
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Cancer therapies; Carcinoma, Endometrioid - mortality; Carcinoma, Endometrioid - pathology; Carcinoma, Endometrioid - therapy; Chemotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial cancer; Endometrial Neoplasms - mortality; Endometrial Neoplasms - pathology; Endometrial Neoplasms - therapy; Endometrium; Ethics; Female; Health care facilities; Histology; Humans; Lymphatic system; Malignancy; Medical prognosis; Medical records; Middle Aged; Multivariate analysis; Myometrium; Neoplasm Staging; Patients; Proportional Hazards Models; Radiation therapy; Radiotherapy, Adjuvant; Regression analysis; Retrospective Studies; Risk analysis; Risk factors; Surgery; Taiwan - epidemiology; Tumors; Uterus - pathology
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph16142561

Adjuvant treatment in advanced-stage (stages III /IV) endometrial carcinomas in terms of tumor grades has not yet been explored. We retrospectively analyzed 194 patients with advanced-stage endometrioid endometrial carcinoma who received surgery, followed by adjuvant therapy, at National Taiwan University Hospital between January 1, 2000 and August 31, 2017. Adjuvant therapies included radiation (RT), chemotherapy alone (CT), and combined modality treatment (CMT: radiation and chemotherapy). The prognostic factors were determined from multivariate survival analyses using Cox regression models. Progression-free survival (PFS) and overall survival (OS) times were estimated with the Kaplan-Meier method. The median follow-up was 45.5 months (range: 6.2-207.9). In grade 1/2 endometrioid carcinoma, neither adjuvant CT nor CMT could prolong PFS significantly compared to RT (CT: HR 1.59, 95% CI 0.64-3.97; CMT: HR 2.03, 95% CI 0.72-5.74). Notably, maximal cytoreduction independently improved PFS (HR 0.31, 95% CI 0.10-0.90). No particular adjuvant treatment provided an OS advantage over the others for grade 1/2 endometrioid carcinomas. However, for grade 3 endometrioid carcinoma, CMT showed OS benefits (HR 0.15, 95% CI 0.03-0.89) compared to RT and CT. In conclusion, maximal cytoreduction should be the goal in patients with grade 1/2 advanced-stage endometrioid carcinomas. Based on our results, patients with grade 3 endometrioid carcinomas might benefit from adjuvant CMT.